Biologic monotherapy in the treatment of rheumatoid arthritis

References

• SilmanAJHochbergMCEpidemiology of the Rheumatic Diseases: Rheumatoid ArthritisNew YorkOxford University Press2001
   Google Scholar
• BrooksPMThe burden of musculoskeletal disease – a global perspectiveClin Rheumatol200625677878116609823
   PubMed Web of Science ®Google Scholar
• ScottDLWolfeFHuizingaTWJRheumatoid arthritisLancet201037697461094110820870100
   PubMed Web of Science ®Google Scholar
• McInnesIBSchettGThe pathogenesis of rheumatoid arthritisN Engl J Med2011365232205221922150039
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsAnn Rheum Dis201069696497520444750
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• SmolenJSAletahaDBijlsmaJWT2T Expert CommitteeTreating rheumatoid arthritis to target: recommendations of an international task forceAnn Rheum Dis201069463163720215140
   PubMed Web of Science ®Google Scholar
• GrigorCCapellHStirlingAEffect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trialLancet2004364943026326915262104
   PubMed Web of Science ®Google Scholar
• ChoquetteDThomasOArundineMLower than expected levels of DMARD acquisition immediately pre and post biologic initiation in rheumatoid arthritis patientsArthritis Rheum201264Suppl 101841
   Google Scholar
• RudermanEMThe role of concomitant methotrexate in biologic therapy for rheumatoid arthritisBull Hosp Jt Dis2013201371 Suppl 1S29S32
   Google Scholar
• KeystoneECBreedveldFCvan der HeijdeDLongterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extensionJ Rheumatol201441151424241487
   PubMed Web of Science ®Google Scholar
• LethabyALopez-OlivoMAMaxwellLBurlsATugwellPWellsGAEtanercept for the treatment of rheumatoid arthritisCochrane Database Syst Rev20135CD00452523728649
   PubMed Web of Science ®Google Scholar
• JansenJPBuckleyFDejonckheereFOgaleSComparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysisHealth Qual Life Outcomes20141210224988902
   PubMed Web of Science ®Google Scholar
• CastrejónIGibsonKAPincusTEfficacy and safety of methotrexate in combination with other non-biologic disease-modifying antirheumatic drugs (DMARDs) in treatment of rheumatoid arthritisBull Hosp Jt Dis2013201371 Suppl 1S20S28
   Google Scholar
• PincusTGibsonKACastrejónIUpdate on methotrexate as the anchor drug for rheumatoid arthritisBull Hosp Jt Dis2013201371 Suppl 1S9S19
   Google Scholar
• ZhangJXieFDelzellEImpact of biologics with and without concomitant MTX and at reduced doses in older rheumatoid arthritis patientsArthritis Care Res (Hoboken) Epub2014114
   Web of Science ®Google Scholar
• EmeryPSebbaAHuizingaTWJBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisAnn Rheum Dis201372121897190423918035
   PubMed Web of Science ®Google Scholar
• YaziciYShiNJohnAUtilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapyBull NYU Hosp Jt Dis2008662778518537774
   PubMedGoogle Scholar
• SolimanMMAshcroftDMWatsonKDLuntMSymmonsDPMHyrichKLImpact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterAnn Rheum Dis201170458358921330639
   PubMed Web of Science ®Google Scholar
• Vicente RabanedaEFHerrero-BeaumontGCastañedaSUpdate on the use of abatacept for the treatment of rheumatoid arthritisExpert Rev Clin Immunol20139759962123899231
   PubMed Web of Science ®Google Scholar
• NashPNayiagerSGenoveseMCImmunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label studyArthritis Care Res (Hoboken)201365571872823097311
   PubMed Web of Science ®Google Scholar
• BreedveldFCWeismanMHKavanaughAFThe PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis Rheum2006541263716385520
   PubMed Web of Science ®Google Scholar
• BresnihanBAnakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectivesClin Exp Rheumatol2002205 Suppl 27S32S3414989427
   PubMed Web of Science ®Google Scholar
• FechtenbaumMMd YusofMYEmeryPCertolizumab pegol in rheumatoid arthritis: current updateExpert Opin Biol Ther201414684185024654999
   PubMed Web of Science ®Google Scholar
• CurtisJRYangSChenLPredicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trialAnn Rheum Dis201271220621221998118
   PubMed Web of Science ®Google Scholar
• CannonGWWangBCParkGSKoenigACollierDHKeystoneECRemission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experienceClin Exp Rheumatol201331691992524237999
   PubMed Web of Science ®Google Scholar
• KeystoneECGenoveseMCHallSGolimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extensionJ Rheumatol20134071097110323678153
   PubMed Web of Science ®Google Scholar
• GenoveseMCHanCKeystoneECEffect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD studyJ Rheumatol20123961185119122505702
   PubMed Web of Science ®Google Scholar
• NamJLRamiroSGaujoux-VialaCEfficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritisAnn Rheum Dis201473351652824399231
   PubMed Web of Science ®Google Scholar
• RichterAStrangfeldAHerzerPSustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a german biologics registerArthritis Care Res (Hoboken)201466111627163324664818
   PubMed Web of Science ®Google Scholar
• WendlerJBurmesterGRSörensenHRituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patientsArthritis Res Ther2014162R8024670196
   PubMed Web of Science ®Google Scholar
• GabayCEmeryPvan VollenhovenRADACTA Study InvestigatorsTocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trialLancet201338198771541155023515142
   PubMed Web of Science ®Google Scholar
• NakashimaYKondoMMiyaharaHIwamotoYDrug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumabDrug Des Devel Ther20148913919
   PubMed Web of Science ®Google Scholar
• LeeEBFleischmannRHallSORAL Start InvestigatorsTofacitinib versus methotrexate in rheumatoid arthritisN Engl J Med2014370252377238624941177
   PubMed Web of Science ®Google Scholar
• MorelandLWAltenRVan den BoschFCostimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusionArthritis Rheum20024661470147912115176
   PubMed Web of Science ®Google Scholar
• SchiffMPritchardCHuffstutterJEThe 6-month safety and effi-cacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialAnn Rheum Dis200968111708171419074911
   PubMed Web of Science ®Google Scholar
• van RielPLvan GestelAMScottDLEULAR handbook of clinical assessments in rheumatoid arthritisAlphen Aan Den Rijn. The NetherlandsVan Zuiden Communications, BV2000154
   Google Scholar
• GottenbergJERavaudPCantagrelAPositivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the ‘Orencia and Rheumatoid Arthritis’ registryAnn Rheum Dis201271111815181922615458
   PubMed Web of Science ®Google Scholar
• van de PutteLBAtkinsCMalaiseMEfficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnn Rheum Dis200463550851615082480
   PubMed Web of Science ®Google Scholar
• NukiGBresnihanBBearMBMcCabeDLong-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trialArthritis Rheum200246112838284612428223
   PubMed Web of Science ®Google Scholar
• BresnihanBAlvaro-GraciaJMCobbyMTreatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonistArthritis Rheum19984112219622049870876
   PubMed Web of Science ®Google Scholar
• BresnihanBNewmarkRRobbinsSGenantHKEffects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trialJ Rheumatol20043161103111115170922
   PubMed Web of Science ®Google Scholar
• FleischmannRVencovskyJvan VollenhovenRFEfficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheu-matic therapy: the FAST4WARD studyAnn Rheum Dis200968680581119015206
   PubMed Web of Science ®Google Scholar
• WeinblattMEFleischmannRHuizingaTWEfficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb studyRheumatology (Oxford, England)2012511222042214
   PubMed Web of Science ®Google Scholar
• BathonJMMartinRWFleischmannRMA comparison of etan-ercept and methotrexate in patients with early rheumatoid arthritisN Engl J Med2000343221586159311096165
   PubMed Web of Science ®Google Scholar
• EmeryPBreedveldFCHallSComparison of methotrexate mono-therapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trialLancet2008372963637538218635256
   PubMed Web of Science ®Google Scholar
• EmeryPBreedveldFvan der HeijdeDCombination of Methotrexate and Etanercept in Early Rheumatoid Arthritis Trial GroupTwo-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized studyArthritis Rheum201062367468220187135
   PubMed Web of Science ®Google Scholar
• van RielPLTaggartAJSanyJAdd Enbrel or Replace Methotrexate Study InvestigatorsEfficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE studyAnn Rheum Dis200665111478148316464988
   PubMed Web of Science ®Google Scholar
• KamedaHKanbeKSatoEContinuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR studyJ Rheumatol20113881585159221572151
   PubMed Web of Science ®Google Scholar
• PopeJEHaraouiBThorneJCVieiraAPoulin-CostelloMKeystoneECThe Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritisAnn Rheum Dis201473122144215123979914
   PubMed Web of Science ®Google Scholar
• KristensenLESaxneTNilssonJGeborekPImpact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenArthritis Res Ther200686R17417121678
   PubMed Web of Science ®Google Scholar
• MainiRNBreedveldFCKaldenJRTherapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis Rheum1998419155215639751087
   PubMed Web of Science ®Google Scholar
• HyrichKLSymmonsDPMWatsonKDSilmanAJComparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying anti-rheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterArthritis Rheum20065461786179416736520
   PubMed Web of Science ®Google Scholar
• EdwardsJCWSzczepanskiLSzechinskiJEfficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritisN Engl J Med2004350252572258115201414
   PubMed Web of Science ®Google Scholar
• OwczarczykKHellmannMFliednerGClinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexateAnn Rheum Dis200867111648164918854518
   PubMed Web of Science ®Google Scholar
• NishimotoNYoshizakiKMiyasakaNTreatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trialArthritis Rheum20045061761176915188351
   PubMed Web of Science ®Google Scholar
• NishimotoNHashimotoJMiyasakaNStudy of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnn Rheum Dis20076691162116717485422
   PubMed Web of Science ®Google Scholar
• JonesGSebbaAGuJComparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnn Rheum Dis2010691889619297346
   PubMed Web of Science ®Google Scholar
• DougadosMKisselKConaghanPGClinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY studyAnn Rheum Dis201473580380924473673
   PubMed Web of Science ®Google Scholar
• LundquistLMColeSWSikesMLEfficacy and safety of tofacitinib for treatment of rheumatoid arthritisWorld J Orthop20145450451125232526
   PubMedGoogle Scholar
• FleischmannRKremerJCushJORAL Solo InvestigatorsPlacebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritisN Engl J Med2012367649550722873530
   PubMed Web of Science ®Google Scholar
• AaltonenKJVirkkiLMMalmivaaraAKonttinenYTNordströmDCBlomMSystematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritisPLoS One201271e3027522272322
   PubMed Web of Science ®Google Scholar
• RamiroSGaujoux-VialaCNamJLSafety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritisAnn Rheum Dis201473352953524401994
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study InvestigatorsTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet2004363941067568115001324
   PubMed Web of Science ®Google Scholar
• van der HeijdeDKlareskogLRodriguez-ValverdeVTEMPO Study InvestigatorsComparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trialArthritis Rheum20065441063107416572441
   PubMed Web of Science ®Google Scholar
• EmeryPFleischmannRMMorelandLWGolimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritisArthritis Rheum20096082272228319644849
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFFleischmannRCohenSORAL Standard InvestigatorsTofacitinib or adalimumab versus placebo in rheumatoid arthritisN Engl J Med2012367650851922873531
   PubMed Web of Science ®Google Scholar
• BurmesterGRBlancoRCharles-SchoemanCORAL Step investigatorsTofacitinib (CP-690,550) in combination with metho-trexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trialLancet2013381986545146023294500
   PubMed Web of Science ®Google Scholar
• van SchouwenburgPARispensTWolbinkGJImmunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNat Rev Rheumatol20139316417223399692
   PubMed Web of Science ®Google Scholar
• KrieckaertCLNurmohamedMTWolbinkGJMethotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent mannerAnn Rheum Dis201271111914191522586169
   PubMed Web of Science ®Google Scholar
• AtzeniFTalottaRSalaffiFImmunogenicity and autoimmunity during anti-TNF therapyAutoimmun Rev201312770370823207283
   PubMed Web of Science ®Google Scholar
• BendtzenKGeborekPSvensonMLarssonLKapetanovicMCSaxneTIndividualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximabArthritis Rheum200654123782378917133559
   PubMed Web of Science ®Google Scholar
• AardenLRuulsSRWolbinkGImmunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurementCurr Opin Immunol200820443143518619538
   PubMed Web of Science ®Google Scholar
• JonesGDingCTocilizumab: a review of its safety and efficacy in rheumatoid arthritisClin Med Insights Arthritis Musculoskelet Disord20103818921234291
   PubMedGoogle Scholar
• KapetanovicMCLarssonLTruedssonLSturfeltGSaxneTGeborekPPredictors of infusion reactions during infliximab treatment in patients with arthritisArthritis Res Ther200684R13116869978
   PubMed Web of Science ®Google Scholar